What are copper peptides, and why is everyone talking about GHK-Cu right now?
Short answer: GHK-Cu is a naturally occurring copper-binding tripeptide that plausibly supports wound healing and collagen turnover — the mechanism is real and decades old. The "70% / 50% / 40% collagen increase" stat driving its current surge is repeated everywhere and traces to one tiny 1998 pilot study whose actual result means something different from what the marketing claims.
GHK (glycyl-L-histidyl-L-lysine) is a three-amino-acid fragment that occurs naturally in human plasma and appears to be released from collagen at wound sites; bound to a copper ion, it becomes GHK-Cu, the form sold in serums [1]. It was first shown to stimulate collagen synthesis in cultured human fibroblasts — skin cells grown in a dish, not skin itself — in 1988, with the effect appearing at very low, physiological-range concentrations [1]. That 1988 finding is real, foundational, and in-vitro: cells in a lab dish, not a study of what a cream does to a face. Worth disclosing here rather than only later: one of that paper's co-authors was Loren Pickart, who had co-founded ProCyte Corporation three years earlier specifically to commercialize copper-peptide products [1] — meaning the commercial interest in this story runs all the way back to the field's foundational paper, not only to the marketing built on it since (more on Pickart's involvement below).
Does GHK-Cu really increase collagen by 70%, elastin by 50%, and glycosaminoglycans by 40%?
No — that specific three-ingredient framing does not check out, and this is worth being precise about because it is the single most-repeated number in copper-peptide marketing. The real study behind it exists, but it measured something different from what gets quoted.
The number traces to a 1998 pilot study (Abdulghani et al., Disease Management and Clinical Outcomes) that applied four different topical creams — a copper-binding peptide cream, vitamin C, melatonin, and tretinoin — to the thigh skin of 20 healthy volunteers (10 per comparison pair) for one month, then took skin biopsies [2]. The actual result: 7 of 10 volunteers using the copper peptide cream showed increased procollagen on immunohistological staining, versus 5 of 10 for vitamin C, 5 of 10 for melatonin, and 4 of 10 for tretinoin [2]. That's where 70%, 50%, and 40% come from — but they describe the proportion of volunteers whose biopsy showed any increase, across four different creams, not a "70% increase in collagen amount" for one ingredient, and definitely not separate percentage gains in collagen, elastin, and glycosaminoglycans, which this study didn't measure as three separate figures at all. That three-part collagen/elastin/GAG version circulating in skincare marketing appears to be a later mutation of the real number, not a restatement of it.
Worth sitting with the study itself, too: 20 people, thigh skin rather than face, one month, never picked up by a PubMed-indexed journal, and partly funded by Revlon Research Center [2] — a cosmetics-industry funder, though not a copper-peptide seller specifically. That's a thin foundation for a stat that's been repeated as settled fact for over two decades.
Who's actually done the research on GHK-Cu?
Mostly one person's company — and that goes back further than the marketing. Loren Pickart, the researcher most associated with popularizing GHK-Cu, co-authored the 1988 fibroblast study described above as the field's foundational finding — three years after he co-founded ProCyte Corporation specifically to commercialize copper-peptide products [1]. He later ran Skin Biology, which sells copper-peptide skincare directly [3]. At least three of the most-cited modern reviews summarizing "what GHK-Cu does" — a 2018 Cosmetics review, a 2015 BioMed Research International review, and a second 2018 review in the International Journal of Molecular Sciences — are authored solely by Pickart and colleagues, listed under Skin Biology's own R&D department, and each declares no conflict of interest despite the authors working for the company that sells the product being reviewed [3][4][6]. That disclosure gap doesn't mean the underlying lab and animal science is wrong, but it means the field's own synthesis of "what's known" — starting with its first paper — has been written almost entirely by the seller, and independent replication is thin. Treat "GHK-Cu does X" claims sourced to these reviews as one company's reading of the literature, not a neutral consensus.
A newer entrant follows the same pattern: in 2026, Yuvan Research Inc., a longevity-biotech startup, put out a press release describing a 21-woman, 3-month trial of its own patented GHK-Cu gel ("Neel"), reporting a 28% average increase in ultrasound-measured skin density and 51% in the top quartile [5]. It's an unpublished business announcement, not a peer-reviewed paper — no full methods or independent verification are available to check the numbers against — and the company both ran the trial and sells the product [5]. That's not evidence GHK-Cu doesn't work; it's evidence that, thirty-plus years on, the pattern of "the seller funds and publishes the proof" hasn't changed.
What does legitimate lab and animal evidence actually show?
Real, but preliminary. In fibroblast cultures — human skin cells grown in a dish — GHK-Cu stimulates collagen synthesis at low concentrations without increasing cell number [1], and later cell-culture work summarized in Pickart's own reviews found it also affects matrix metalloproteinase expression, enzymes involved in remodeling skin's structural proteins [6]. In rat wound models — animal evidence, not human — GHK-Cu accelerated the accumulation of connective tissue at wound sites, per the same reviews [6]. These are legitimate, mechanistically interesting findings, and they're the actual basis for calling GHK-Cu's biology "plausible." They are not evidence that a copper-peptide serum measurably changes human facial skin over any specific timeframe.
Is there any real human trial evidence?
Some, and it's genuinely mixed rather than damning. Beyond the small, industry-funded 1998 pilot, later industry-linked human work has reported reductions in wrinkle measurements after GHK-Cu use compared with other actives, though those trials are also small, short, and sponsored by companies selling copper-peptide products [3]. No large, independent, peer-reviewed randomized trial comparing a copper-peptide serum against placebo on facial skin over months — the kind of evidence base retinoids and daily sunscreen have — currently exists for GHK-Cu.
Is a copper-peptide serum worth using?
If it's already in a product you like, there's a real, decades-old mechanistic case for it and no red-flag safety signal in the evidence reviewed here. But treat "clinically proven to boost collagen 70%" language on a label as marketing shorthand for a number that doesn't mean what it's implied to mean, sourced overwhelmingly to research run or funded by companies selling the ingredient. It belongs in the same category as other trending peptides: a plausible mechanism, small industry-run trials, and evidence that hasn't caught up to the online hype cycle. Run any copper-peptide product through our ingredient scanner to see what else is actually in the formula before assuming the headline ingredient is doing the work.
FAQ
Where does the "70/50/40%" copper peptide stat actually come from?
A 1998 pilot study of 20 people that found 7 of 10 thigh-skin biopsies showed more procollagen after a month of copper-peptide cream, versus 5 of 10 for vitamin C, 5 of 10 for melatonin, and 4 of 10 for tretinoin [2]. That's a proportion of responders in a tiny, unreplicated study — not a 70% increase in collagen output, and not separate figures for collagen, elastin, and glycosaminoglycans.
Is GHK-Cu the same thing as "copper tripeptide-1"?
Yes — copper tripeptide-1 is the INCI (ingredient-list) name for the GHK-copper complex discussed here.
Can copper peptides replace retinoids or sunscreen?
No trial has tested that head-to-head, and nothing in the evidence reviewed here supports treating copper peptides as a substitute for either. Both retinoids and daily sunscreen have far larger, more independent evidence bases.
